

Cemiplimab R2810-ONC-1423/R2810-ONC-1540

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Cemiplimab R2810-ONC-1423/R2810-ONC-1540

### SCORE

**CURATIVE**




Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Skin Cancers  
 Therapeutic Indication: For the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation  
 Experimental Arm: Cemiplimab  
 Control Arm: Single arm (Phase II)



